Rosetta Genomics this month announced that it has scaled back its work on a serum-based colon cancer-screening assay based on microRNA biomarkers, less than a year after the company said that commercialization of the test, dubbed miRscreen Colon, had become its top priority.
People carrying the germ-line MSH6 mutation are at high risk by age 80 years for colorectal and endometrial cancers and any cancer associated with Lynch syndrome, according to a new study published online December 22 in the Journal of the National Cancer Institute. It is known that mutations in MSH6 account for 10%-20% of Lynch syndrome, which causes colorectal and other cancers, but less is
WILTON — Nobody wants to talk about poop but isn’t it better than talking about a cancer diagnosis? As a college student in good health, Molly McMaster did not want to talk about it either. She had a number of symptoms that went undiagnosed. McMaster attributed her “stomach issues” to everything from something she ate to being lactose intolerant to girl issues. Eventually she realized her
A set of gene-expression profiles may be able to help oncologists better pick chemotherapies in about 80 percent of cases in three types of cancer, according to scientists at Duke University’s Institute for Genome Sciences and Policy.
GARDNERVILLE, Nev. - Two months ago, Mike Biaggini got the news that his eight-year battle against colon cancer was just about over. "I was told by my doctors that the treatment regimen would shorten my life, that it would not do my family or me any good," Biaggini said in a recent interview from his Gardnerville Ranchos home. The prognosis followed a gastro-intestinal bleed that sent the 55
Contact:
Copyright © 2005 Colon Cancer Solutions.com All Rights Reserved